Breast Imaging

What Is the Right Initial Imaging for an Indeterminate Male Breast Mass?

·
What Is the Right Initial Imaging for an Indeterminate Male Breast Mass?

A 48-year-old man presents to your clinic after noticing a firm, non-tender lump in his right breast a few weeks ago. On examination, you confirm a palpable, somewhat mobile 1.5 cm mass in the subareolar region. It doesn’t have the classic features of gynecomastia, and there are no skin changes, nipple discharge, or palpable axillary nodes. You need to determine the best initial imaging study to evaluate this indeterminate finding and rule out malignancy. This article provides a step-by-step clinical workflow for this exact scenario, grounded in the American College of Radiology (ACR) Appropriateness Criteria. For a male patient 25 years or older with an indeterminate palpable breast mass, the ACR rates a `Digital breast tomosynthesis diagnostic` as Usually Appropriate.

Who Fits This Clinical Scenario?

This guidance is specifically for the initial imaging workup of a male patient, 25 years of age or older, who presents with a palpable breast mass that is considered indeterminate after a thorough clinical history and physical examination. “Indeterminate” means the finding is not clearly benign, such as classic, bilateral, symmetric gynecomastia, nor is it highly suspicious for malignancy with features like skin retraction, ulceration, or bloody nipple discharge.

This workflow does not apply to several similar-sounding but distinct clinical situations, which have their own evaluation pathways:

  • Males younger than 25 years: In this age group, malignancy is exceedingly rare, and the imaging approach is different, often starting with ultrasound.
  • Classic gynecomastia: If the physical exam reveals a classic, tender, concentric, disc-like subareolar mass, especially if bilateral, this is managed as gynecomastia, for which imaging is often not required.
  • Highly suspicious findings: Patients with a mass that is hard, fixed to the skin or chest wall, associated with skin changes, or accompanied by suspicious axillary adenopathy should be managed on an expedited pathway, as these findings are concerning for breast cancer.

Correctly identifying that your patient fits this specific scenario—an adult male over 25 with a palpable but clinically ambiguous breast lump—is the crucial first step to ordering the most appropriate initial imaging.

What Diagnoses Are You Working Up in This Scenario?

When ordering imaging for an indeterminate palpable mass in an adult male, the primary goal is to differentiate benign from malignant etiologies. While male breast cancer is rare, accounting for less than 1% of all breast cancers, it must be the primary consideration to rule out due to its clinical significance.

Male Breast Cancer: This is the most consequential diagnosis in the differential. It typically presents as a painless, firm, subareolar mass. Because men have less breast parenchyma, tumors can invade the nipple-areolar complex, skin, or underlying pectoralis muscle earlier than in women. Imaging is critical for characterizing the mass and detecting features suspicious for malignancy.

Gynecomastia: This is the most common cause of a palpable male breast mass and represents benign proliferation of glandular tissue. While it often presents as a classic symmetric, tender, subareolar disc, it can also be asymmetric, unilateral, or present as a more focal, firm nodule, making it clinically indeterminate and requiring imaging to differentiate from cancer.

Benign Tumors and Lesions: A variety of other benign conditions can present as palpable masses. These include lipomas (fatty tumors), epidermal inclusion cysts (sebaceous cysts), pseudoangiomatous stromal hyperplasia (PASH), fibromas, or hematomas from prior trauma. While less common than gynecomastia, these entities are important considerations that imaging can often definitively diagnose.

Why Is Diagnostic Digital Breast Tomosynthesis the Recommended Study?

For an indeterminate palpable mass in a male aged 25 or older, the ACR identifies both `Digital breast tomosynthesis diagnostic` and `Mammography diagnostic` as Usually Appropriate. Tomosynthesis, or 3D mammography, is often preferred as it provides a distinct advantage in this clinical setting.

Digital breast tomosynthesis (DBT) acquires multiple low-dose images of the breast from different angles, which are then reconstructed into thin, one-millimeter slices. This technique reduces the effect of overlapping tissue, a common issue in mammography that can obscure or mimic lesions. In the male breast, which is typically smaller and may have dense glandular tissue from gynecomastia, DBT’s ability to “scroll” through the tissue can significantly improve the radiologist’s ability to see lesion margins and architecture, increasing diagnostic confidence and reducing the need for additional imaging views.

The radiation dose for both diagnostic mammography and DBT is low, categorized by the ACR as ☢☢ (0.1-1 mSv), which is a minimal risk in the context of evaluating a potentially malignant mass.

Why are other studies rated lower for initial evaluation?

  • US breast: Ultrasound is rated as May be appropriate. While it is excellent for characterizing masses (e.g., cystic vs. solid) and guiding biopsies, it is typically used as an adjunct to mammography, not as the initial standalone study in this age group. Mammography provides a global view of all breast tissue, including the detection of suspicious calcifications, which ultrasound may miss. Ultrasound is most often used to further evaluate a specific finding seen on mammography.
  • MRI breast without and with IV contrast: An MRI is rated as Usually not appropriate for the initial workup of a palpable mass. While highly sensitive, breast MRI has lower specificity, which can lead to false positives and unnecessary biopsies. Its primary roles are in staging known cancer, evaluating for recurrence, or as a problem-solving tool in complex cases, not as a first-line diagnostic test for a palpable lump.

When ordering, it is critical to specify “diagnostic” rather than “screening.” A diagnostic mammogram or tomosynthesis study is performed under the direct supervision of a radiologist, who can request additional specialized views or a targeted ultrasound in real-time to complete the evaluation in a single visit.

What’s Next After Diagnostic Digital Breast Tomosynthesis? Downstream Workflow

The results of the diagnostic tomosynthesis will guide your next steps, typically categorized using the Breast Imaging Reporting and Data System (BI-RADS) score. The downstream workflow is a clear decision tree based on these findings.

If the result is suspicious (BI-RADS 4 or 5): A finding categorized as suspicious or highly suggestive of malignancy requires tissue sampling. The next step is a referral for an ultrasound-guided core needle biopsy of the mass. The radiologist will have likely already recommended this in the report. This is the definitive step to establish a diagnosis of breast cancer or another pathology.

If the result is benign or negative (BI-RADS 1 or 2): If the imaging is entirely negative or shows features classic for a benign entity like gynecomastia or a lipoma, no further imaging workup is needed. The patient can be reassured. Clinical follow-up is still warranted to ensure the palpable finding corresponds to the benign imaging finding and remains stable over time.

If the result is indeterminate (BI-RADS 0 or 3): A BI-RADS 0 assessment means the evaluation is incomplete, and additional imaging is required. This almost always means a targeted ultrasound of the palpable area is needed for further characterization. A BI-RADS 3 finding (“probably benign”) implies a very low likelihood of malignancy (<2%), but short-term imaging follow-up (typically at 6 months) is recommended to ensure stability. This situation routes the patient to the next logical step in the ACR criteria: “Male 25 years of age or older with indeterminate palpable breast mass. Mammography or digital breast tomosynthesis indeterminate.”

Pitfalls to Avoid (and When to Get Help)

Navigating the workup of a male breast mass requires careful attention to avoid common missteps that can delay diagnosis or cause unnecessary procedures.

  • Ordering a “screening” mammogram: A patient with a palpable symptom requires a “diagnostic” study. Ordering a screening exam will likely be rejected by the imaging facility or result in an incomplete workup requiring a callback.
  • Ignoring a persistent palpable lump: If the mammogram is reported as negative (BI-RADS 1) but you can still clearly feel the mass, this is a “palpable-mammographically occult” finding. Do not stop the workup. The next step must be a targeted ultrasound of the palpable area of concern.
  • Incomplete physical exam: Always perform a comprehensive breast and axillary exam. Failing to document palpable axillary lymph nodes can lead to an underestimation of the clinical suspicion and potential under-staging if cancer is found.
  • Assuming all male breast masses are gynecomastia: While gynecomastia is the most common cause, any eccentric, non-tender, or hard mass should be considered suspicious until proven otherwise with appropriate imaging.

If the clinical and imaging findings are discordant (e.g., a highly suspicious physical exam with negative imaging), escalate by consulting with the breast radiologist or referring the patient to a breast surgeon for evaluation.

Related ACR Topics and Tools

This article focuses on one specific clinical scenario. For a comprehensive overview of all related presentations, or to explore the technical details of the recommended imaging studies, the following resources are available.

Frequently Asked Questions

Why not just order an ultrasound first for a palpable mass in a man over 25?

While ultrasound is excellent for targeted evaluation and characterization, mammography or tomosynthesis is the recommended initial study because it provides a comprehensive view of the entire breast. It is superior for detecting suspicious microcalcifications, which can be an early sign of cancer and may be missed on ultrasound. Mammography serves as the foundational exam, with ultrasound typically used as a follow-up to clarify any findings.

What is the practical difference between a ‘screening’ and a ‘diagnostic’ mammogram?

A screening mammogram is a routine exam for asymptomatic individuals and involves a standard set of images. A diagnostic mammogram is ordered for a patient with a specific symptom, like a palpable lump. It is directly supervised by a radiologist who can tailor the exam with additional views (e.g., magnification, spot compression) or add a same-day ultrasound to provide a complete answer in one visit.

Is digital breast tomosynthesis (DBT) significantly better than standard 2D mammography for men?

Both are rated ‘Usually Appropriate’ by the ACR. However, DBT (3D mammography) is often preferred because it reduces the effect of overlapping tissue. This can be particularly helpful in differentiating a true mass from superimposed benign glandular tissue (gynecomastia), potentially increasing diagnostic accuracy and reducing the rate of callbacks for additional imaging.

If the patient has a history of pectoral implants, does that change the initial imaging recommendation?

Yes, the presence of implants can alter the approach. While mammography (with specialized implant-displaced views) is still the primary modality, ultrasound may play a larger initial role. The palpable lump needs to be localized as being within the breast tissue versus related to the implant or capsule. This is a more complex scenario where direct consultation with the radiologist before ordering is often beneficial.

How concerned should I be about the radiation from a diagnostic mammogram?

The radiation dose from a diagnostic mammogram or tomosynthesis is very low, approximately 0.1-1 mSv. This is equivalent to a few months of natural background radiation that everyone is exposed to. The clinical benefit of accurately diagnosing or ruling out breast cancer far outweighs the minimal risk associated with this low level of radiation exposure.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026